Skip to content

Clinical trials

Phase 2 Leukemia, Promyelocytic, Acute trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Promyelocytic, Acute Phase: Phase 2 Clear all

40 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20021
20031
20042
20063
20075
20081
20092
20102
20114
20121
20132
20181
20191
20211
20231

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed25
Terminated5
Recruiting4
Unknown status4
Withdrawn2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Memorial Sloan Kettering Cancer Center6
National Cancer Institute (NCI)5
M.D. Anderson Cancer Center3
Alliance for Clinical Trials in Oncology2
Case Comprehensive Cancer Center2
Fred Hutchinson Cancer Center2
Northwestern University2
The University of Hong Kong2
Aegera Therapeutics1
Associazione Italiana Ematologia Oncologia Pediatrica1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Promyelocytic, Acute40
Leukemia, Myeloid, Acute19
Leukemia18
Leukemia, Myelomonocytic, Acute14
Leukemia, Erythroblastic, Acute11
Congenital Abnormalities10
Leukemia, Monocytic, Acute10
Myelodysplastic Syndromes10
Leukemia, Megakaryoblastic, Acute9
Leukemia, Lymphocytic, Chronic, B-Cell6

Trials

Showing 76 to 40 of 40. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.